(Q43278531)
Statements
1 reference
Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome (English)
1 reference
Larry D Lynd
1 reference
Mehdi Najafzadeh
1 reference
Lindsey Colley
1 reference
Michael F Byrne
1 reference
Andrew R Willan
1 reference
Mark J Sculpher
1 reference
F Reed Johnson
1 reference
A Brett Hauber
1 reference
10 September 2009
1 reference
1 reference
13
1 reference
4
1 reference
411-417
1 reference
Identifiers
1 reference
1 reference